Clinical research

SURMOUNT-3: Tirzepatide after intensive lifestyle intervention

Phase 3 randomised placebo-controlled trial following an intensive lifestyle intervention lead-in. 806 randomised, over 72 weeks. Sponsor: Eli Lilly and Company.

SURMOUNT-3 (NCT04657016) tested at Maximum tolerated, 10 or 15 mg against placebo in adults with overweight or obesity who completed a 12-week intensive lifestyle intervention.−18.4% additional reduction versus +2.5% with placebo, on top of lead-in weight loss Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

Results

−18.4% additional reduction versus +2.5% with placebo, on top of lead-in weight loss

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

Industry-funded. The lifestyle lead-in selects for people who already responded to lifestyle intervention, which limits generalisability.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.